Generex Biotechnology Announces Investor Conference Call Agenda Wednesday, January 16, at 4:00 p.m. Eastern

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) today announced an agenda for the investor conference call to be presented today, Wednesday January 16, at 4:00 p.m. Eastern time. Joseph Moscato, Chief Executive Officer of Generex will outline the company’s strategic and financial plans, including details on financing transactions pertaining to the previously reported acquisitions of the Veneto Group assets and Olaregen. Additionally, Mr. Moscato will review the recent anticipated acquisitions of several profitable and innovative companies in the medical and surgical supply business, which include Pantheon Medical, MediSource, and most recently, Fuse Medical, a publicly traded company with nearly $30 million in projected annual revenues. In addition, Generex has signed a letter of intent for $15 million equity line of credit on more favorable terms than the equity line of credit previously reported.

Importantly, tomorrow, January 17, 2019 (the report date), Generex will declare a dividend in the company’s wholly-owned subsidiary, NuGenerex Immuno-Oncology (formerly Antigen Express). The dividend will be structured such that for every 4 shares of Generex stock held on February 25, 2019 (the projected dividend payment date), investors will receive 1 share of NuGenerex Immuno-Oncology. Immediately following the dividend payout, Generex plans to list NuGenerex Immuno-Oncology on a public exchange. Additional details on this dividend will be provided on the conference call and in subsequent announcements.

“Generex is advancing our strategic initiatives to build value for our investors,” stated Mr. Moscato. “And we are very happy to announce that Generex has signed a Letter of Intent to acquire Fuse Medical, subject to completed due diligence. The transaction has been structured as an all-stock deal valued at $34 million of Generex common stock at $2.50 per share with the potential for earnouts based on certain performance in 2019. The deal is not dilutive to our shareholders, as the payment is being made from the Generex pool shares that are described in the December 4, 2018 8K filing. Fuse is a publicly-traded surgical supply company with revenues approaching $30 million and EBITDA of approximately $5 million. The company distributes a broad portfolio of specialty surgical products to healthcare providers nationwide, bringing not only sales and distribution channels, but also a network of customers that will advance the Generex mission to deliver innovative end-to-end solutions to our healthcare partners, physicians, and patients. I will provide details on these potential acquisitions as well as on our plan to further expand the company’s footprint through the acquisition of a health system management company with a network of 13 hospitals in several states.”

Mr. Moscato continued, “I am also pleased to announce that we have been able to restructure our $35 million debt obligation in a timely manner with the Veneto Group partners, through an agreement on the payment of $15.75 million in Generex common stock at the up-market price of $2.50 per share, that satisfies a significant portion of the $35 million obligation, plus $20 million in cash or stock to follow within 90 Days. The payment to the Veneto Group partners is being made with already accounted for shares in the Generex pool (See 8K on 12/4/18), which is non-dilutive to our current shareholders, as the total number of outstanding shares and capital structure remain the same. Additional information will be discussed at the conference call, followed by an 8k filing. The stock transaction demonstrates the Veneto Groups confidence in our strategic growth plan, because the deal is at a significant premium to our current market valuation. In addition to the Veneto deal, we have agreed to increase the Generex ownership of Olaregen Therapeutix, our regenerative medicine subsidiary, from 51% to approximately 72% through an agreement to acquire all of Olaragen’s outstanding Series A Preferred Stock in exchange for Generex stock and a second payment of either stock or cash. Again, these stock transactions are non-dilutive to our current shareholders, and reserve cash for advancing the company’s strategic plans. Further, we are in discussions with the remaining Olaregen shareholders to acquire up to 100% of the company.”

Lastly, by the end of the month, Generex expects to receive the final audit report on the direct to patient pharmacy network, which the company had previously announced in a letter of intent to acquire the network of pharmacies and IT systems. The audit report will enable Generex to finalize the terms and price of the acquisition, thereby providing a path toward integration of the pharmacy network into NuGenerex Distribution Solutions in the near future. “We’re excited about the opportunity to potentially expand our pharmacy network that ultimately will enhance our distribution and direct to patient capabilities. We look forward to integrating the pharmacy’s cutting edge database systems and operational capabilities to grow our Distribution Solutions business with by introducing a number of innovative pharmacy programs,” stated Terry Thompson, COO of Generex and President of NuGenerex Distribution Solutions.

On the conference call, Mr. Moscato will provide more in depth details on the Company’s financing initiatives, an overview of the recent potential acquisitions in the medical & surgical supply business, an update on the impending commercial launch of Olaregen’s wound healing product Excellagen™, and a review of the pending acquisition of the pharmacy network, IT systems, and direct to patient databases. Mr. Moscato will also provide information regarding the dividend and spin out of NuGenerex Immuno-Oncology, and will wrap up the call with an update on the plan for up-listing Generex to a major stock exchange. Generex will be filing 8Ks with the SEC covering the information shared on the conference call and in corporate communications.

Mr. Moscato concluded, “As always, we will leave sufficient time at the end of call to address any and all questions from our loyal Generex shareholders, and I look forward to an informative discussion on Wednesday afternoon.”

The access information for the investor conference call is as follows:

Wednesday January 16, at 4:00 p.m. Eastern time

Domestic US/Canada – 1-(866) 342-8588

Direct Toll / International - 1-(203) 518-9865

Conference ID - 85014

About Generex Biotechnology Corp.

Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.

Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

Cautionary Note Regarding Forward-Looking Statements

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plan," "believes," "will," "achieve," "anticipate," "would," "should," "subject to" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.

View source version on businesswire.com: https://www.businesswire.com/news/home/20190116005455/en/